Roche Reports Upbeat Efficacy Data From Phase II Obesity Study
RHHBY reports encouraging phase II data as CT-388 delivers strong, sustained weight loss and metabolic benefits in adults with obesity or overweight.
Zacks·5h ago
More News
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in platinum-resistant ovarian cancer.
Zacks·5d ago
European ETFs in Spotlight Following Trump's Tariff Retreat at Davos
Trump's Davos tariff retreat sparks a relief rally, putting European ETFs like FEZ back in focus after transatlantic trade-war fears ease.
Zacks·6d ago
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Zacks·6d ago
Roche's Genentech Expands Investment in North Carolina Facility to $2B
Roche more than doubles Genentech's Holly Springs biomanufacturing investment to approximately $2B, boosting U.S. supply-chain resilience and metabolic drug production.
Zacks·7d ago
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
Zacks·9d ago
CytomX Stock Rises 31% in a Month: Here's What You Should Know
CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.
Zacks·9d ago
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.
Zacks·14d ago
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
Zacks·16d ago
Bull of the Day: Eli Lilly (LLY)
Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.